← FDA DRUG APPROVALS

FDA NDA · NDA021548

LEXIVA

Sponsor: VIIV HLTHCARE

APPLICATION
NDA021548
TYPE
NDA
ORIGINAL APPROVAL
2003-10-20
LATEST ACTION
2019-03-28
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued

Products

LEXIVA · ReferenceDiscontinued
FOSAMPRENAVIR CALCIUM EQ 700MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · TABLET · ORAL

Approval history

2019-03-28Labeling · Supplement 41 · standardLetterAP
2017-12-01Labeling · Supplement 40 · standardLabelAP
2016-09-15Labeling · Supplement 39 · 901 requiredLetterAP
2016-03-22Labeling · Supplement 37 · standardLabelAP
2016-03-10Manufacturing (CMC) · Supplement 38 · standardAP
2015-07-17Labeling · Supplement 35 · standardLetterAP
2015-03-27Labeling · Supplement 36 · 901 requiredLabelAP
2013-10-29Manufacturing (CMC) · Supplement 33 · standardAP
2013-08-28Manufacturing (CMC) · Supplement 30 · standardAP
2013-03-05Manufacturing (CMC) · Supplement 32 · standardAP
2013-02-12Labeling · Supplement 31 · standardLabelAP
2012-04-27Efficacy · Supplement 28 · priorityPediatric Written RequestAP
2012-02-17Labeling · Supplement 29 · 901 requiredLetterAP
2011-05-10Labeling · Supplement 26 · standardLabelAP
2010-04-26Labeling · Supplement 24 · unknownLabelAP
2009-09-11Labeling · Supplement 21 · standardLabelAP
2009-04-14Labeling · Supplement 20 · standardLetterAP
2008-04-30Labeling · Supplement 19 · standardLetterAP
2008-03-05Labeling · Supplement 17 · standardLabelAP
2008-02-20Labeling · Supplement 16 · standardLetterAP
2007-12-14Labeling · Supplement 15 · standardLetterAP
2007-12-13Labeling · Supplement 14 · standardLetterAP
2007-10-12Efficacy · Supplement 13 · unknownLetterAP
2007-02-07Labeling · Supplement 10 · standardLabelAP
2006-11-14Labeling · Supplement 11 · standardLetterAP
2006-08-07Labeling · Supplement 9 · standardLetterAP
2006-05-11Labeling · Supplement 8 · standardLetterAP
2006-03-10Labeling · Supplement 7 · standardLetterAP
2005-11-10Labeling · Supplement 5 · standardLetterAP
2005-06-13Labeling · Supplement 4 · standardLabelAP
2004-11-29Labeling · Supplement 2 · standardLetterAP
2003-10-20Type 2 - New Active Ingredient · Original · standardLetterAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →